Hyundai Bioscience USA and the University of California San Diego (UCSD) have agreed to conduct a clinical trial to evaluate the efficacy of Xafty, a niclosamide-based antiviral, in treating long Covid.

“This is an outstanding opportunity for UCSD  and Hyundai Bioscience to partner together to tackle long Covid,” Professor Davey Smith, Director of the UCSD Altman Clinical and Translational Research Institute (ACTRI) of UCSD and an authority on viral illnesses, especially Covid, said about the collaboration. “There is no therapy currently available for the condition, which affects millions of people around the world.”

Xafty, an oral antiviral agent, is a new drug that improved the bioavailability of niclosamide, which is known to have antiviral efficacy against more than 30 viruses.

It is currently in a Phase III clinical trial in Korea targeting high-risk groups for Covid-19 and is expected to apply for Phase III approval in the US soon.

In a previous Phase II clinical trial, Xafty demonstrated a faster symptom improvement rate than other existing treatments, especially in high-risk groups.

“Being able to reduce symptoms during acute Covid-19 is an impressive accomplishment,” Dr Smith, who has helped run numerous antiviral trials in Covid-19, HIV, and Mpox, said. “Many large recent trials testing antivirals have not had such success. We hope that the clinical trial will be successful and provide a practical treatment option for long Covid patients, which will be historic.”

Xafty is expected to resolve the complex symptoms of long Covid through inflammation inhibition and neuro-protection mechanisms, rather than simply suppressing the virus.

In a recent Parkinson’s disease preclinical study, Xafty promoted dopamine production and nerve cell recovery, suggesting that it could improve symptoms such as brain fog and cognitive impairment due to nerve damage in people with long Covid.

Diana Spencer, Senior Digital Content Editor, DDW